Nektar Therapeutics Stock price

Equities

NKTR

US6402681083

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.9342 USD +5.55% Intraday chart for Nektar Therapeutics +4.11% +65.35%
Sales 2024 * 72.54M Sales 2025 * 68.35M Capitalization 172M
Net income 2024 * -168M Net income 2025 * -167M EV / Sales 2024 * 0.78 x
Net cash position 2024 * 115M Net cash position 2025 * 281M EV / Sales 2025 * -1.61 x
P/E ratio 2024 *
-1.1 x
P/E ratio 2025 *
-1.4 x
Employees 137
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.99%
More Fundamentals * Assessed data
Dynamic Chart
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC CI
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata MT
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating MT
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata CI
Transcript : Nektar Therapeutics, Q4 2023 Earnings Call, Mar 04, 2024
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M MT
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC CI
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer MT
Transcript : Nektar Therapeutics Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM
Nektar Therapeutics(NasdaqCM:NKTR) dropped from NASDAQ Biotechnology Index CI
Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255 MT
North American Morning Briefing : Investors Weigh -2- DJ
More news
1 day+5.55%
1 week+4.11%
Current month+31.58%
1 month+29.75%
3 months+69.24%
6 months+53.15%
Current year+65.35%
More quotes
1 week
0.84
Extreme 0.84
0.94
1 month
0.72
Extreme 0.715
1.08
Current year
0.48
Extreme 0.48
1.08
1 year
0.41
Extreme 0.4126
1.12
3 years
0.41
Extreme 0.4126
20.90
5 years
0.41
Extreme 0.4126
37.00
10 years
0.41
Extreme 0.4126
111.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 06-12-31
Chairman 66 91-11-30
Director of Finance/CFO 58 23-04-16
Members of the board TitleAgeSince
Director/Board Member 65 09-12-31
Director/Board Member 70 00-07-31
Chairman 66 91-11-30
More insiders
Date Price Change Volume
24-03-28 0.9342 +5.55% 1,316,239
24-03-27 0.8851 -1.66% 1,241,878
24-03-26 0.9 +1.34% 1,467,857
24-03-25 0.8881 -2.78% 1,708,466
24-03-22 0.9135 +1.81% 778,497

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.9342 USD
Average target price
1 USD
Spread / Average Target
+7.04%
Consensus
  1. Stock
  2. Equities
  3. Stock Nektar Therapeutics - Nasdaq